Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Cash

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Cancer|July 30, 2019
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology GroupRyan D Roberts, Michael M Lizardo, Damon R Reed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialThomas Cash, Araz Marachelian, Steven G DuBois, et al.
Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Cancer|July 30, 2019
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology GroupRyan D Roberts, Michael M Lizardo, Damon R Reed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2025
Phase I Study of <sup>131</sup>I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy TrialThomas Cash, Araz Marachelian, Steven G DuBois, et al.
Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
Pageof 5